NCT06128551
Study arms updated — PHASE1
NCT06128551 • Phase 1
Enrollment 210→534 (154%) — PHASE1
NCT06128551 • Phase 1 • Enrollment 210→534 (+154%)
Primary endpoint added: Changes in vital signs in Phase 1b — PHASE1
NCT06128551 • Phase 1
Locations updated — PHASE1
NCT06128551 • Phase 1